IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway

被引:28
作者
Joss, A [1 ]
Akdis, M [1 ]
Faith, A [1 ]
Blaser, K [1 ]
Akdis, CA [1 ]
机构
[1] Swiss Inst Allergy & Asthma Res, SIAF, CH-7270 Davos, Switzerland
关键词
T lymphocyte; IL-10; CD28; suppression; phosphatidylinositol; 3-kinase;
D O I
10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
IL-10 induces T cell anergy in numerous mouse models and specific immunotherapy of allergy in humans. Here, we demonstrate that IL-10 directly acts on T cells which are stimulated via CD28 by efficiently blocking proliferation and cytokine production. T cells tolerized by IL-10 showed high viability and the unresponsive state was reversed by anti-CD3 monoclonal antibody (mAb) stimulation and IL-2, but not by anti-CD28 mAb stimulation. Signal transduction via CD28 requires CD28 tyrosine phosphorylation and binding of phosphatidylinositol 3-kinase. IL-10 inhibited tyrosine phosphorylation of CD28; thus, the phosphatidylinositol 3-kinase binding to CD28 was blocked. Consequently, IL-10 inhibited the antigen-induced secretion of both Th1 and Th2 cytokines, including IL-2, IFN-gamma, IL-4, IL-5 and IL-13. Furthermore, neutralization of endogenously produced IL-10 significantly increased T cell proliferation and both Th1 and Th2 cytokine production in vitro. Using superantigen stimuli, T cell suppression by IL-10 was merely induced at low doses when co-stimulation by CD28 was essential. Together, these data demonstrate that IL-10 directly acts on the CD28 signaling pathway and this represents an important T cell suppression mechanism leading to anergy.
引用
收藏
页码:1683 / 1690
页数:8
相关论文
共 47 条
[1]
Role of interleukin 10 in specific immunotherapy [J].
Akdis, CA ;
Blesken, T ;
Akdis, M ;
Wüthrich, B ;
Blaser, K .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (01) :98-106
[2]
IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy [J].
Akdis, CA ;
Blaser, K .
FASEB JOURNAL, 1999, 13 (06) :603-609
[3]
Epitope-specific T cell tolerance to phospholipase A(2) in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro [J].
Akdis, CA ;
Akdis, M ;
Blesken, T ;
Wymann, D ;
Alkan, SS ;
Muller, U ;
Blaser, K .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (07) :1676-1683
[4]
Akdis M, 1997, J IMMUNOL, V159, P4611
[5]
Akdis M, 1999, J IMMUNOL, V163, P466
[6]
HIGH-LEVELS OF INTERLEUKIN-10 PRODUCTION IN-VIVO ARE ASSOCIATED WITH TOLERANCE IN SCID PATIENTS TRANSPLANTED WITH HLA MISMATCHED HEMATOPOIETIC STEM-CELLS [J].
BACCHETTA, R ;
BIGLER, M ;
TOURAINE, JL ;
PARKMAN, R ;
TOVO, PA ;
ABRAMS, J ;
MALEFYT, RD ;
DEVRIES, JE ;
RONCAROLO, MG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :493-502
[7]
MAINTENANCE OF CLONAL ENERGY BY ENDOGENOUSLY PRODUCED IL-10 [J].
BECKER, JC ;
CZERNY, C ;
BROCKER, EB .
INTERNATIONAL IMMUNOLOGY, 1994, 6 (10) :1605-1612
[8]
REVERSAL OF INVITRO T-CELL CLONAL ANERGY BY IL-2 STIMULATION [J].
BEVERLY, B ;
KANG, SM ;
LENARDO, MJ ;
SCHWARTZ, RH .
INTERNATIONAL IMMUNOLOGY, 1992, 4 (06) :661-671
[9]
BLAY JY, 1993, BLOOD, V82, P2169
[10]
DE WMR, 1991, J EXP MED, V174, P1209